潤和軟件(300339.SZ)擬轉讓菲耐得100%股份
格隆匯 8 月 25日丨潤和軟件(300339.SZ)公佈,公司與北京太極華保科技股份有限公司(“太極華保”)於2020年8月24日簽署了《股份轉讓意向協議》,約定初步協商同意由太極華保或其指定的公司以發行股權及支付現金的方式收購公司全資子公司上海菲耐得信息科技有限公司(“菲耐得”)100%股份。此次股份轉讓完成後,菲耐得將成為太極華保或其指定公司的全資子公司,不再納入公司合併報表範圍。
公司此次轉讓菲耐得股份的目的旨在進一步聚焦經營戰略、明晰主營業務、優化資產結構、提高資產質量、改善公司經營與財務狀況。此次交易完成後,公司將不再持有菲耐得的股權,菲耐得將不再納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.